Division of Gastroenterologic and General Surgery, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.
J Am Coll Surg. 2011 Jul;213(1):130-6; discussion 136-8. doi: 10.1016/j.jamcollsurg.2011.03.029. Epub 2011 Apr 13.
Hepatic resection of metastatic carcinoid cancer can prolong survival and control symptomatic endocrinopathy. Decompensated carcinoid heart disease (CHD) can develop in some patients with metastatic carcinoid cancers, which can preclude operation for resectable hepatic metastases. We hypothesized that outcomes after hepatic resection for patients with the carcinoid syndrome after valve replacement for CHD would be similar to carcinoid patients without CHD.
We compared the survival and symptom control after hepatic resection for patients undergoing valve replacement for CHD to carcinoid patients without CHD matched for age, sex, and extent of hepatectomy.
Fourteen patients with earlier valve replacement for CHD were compared with 28 carcinoid patients without CHD. All patients had hepatic resection for metastatic carcinoid disease and carcinoid syndrome. Mean age, sex distribution, and extent of hepatectomy (major hepatectomy, 78%) was similar between groups. Mean interval from valve replacement to hepatectomy was 101 days. There was no operative mortality. Major operative morbidity, inclusive of operative blood loss and cardiorespiratory events, occurred in 28.5% and 14.2% for CHD and non-CHD groups, respectively (p = 0.16). Symptom-free survival for CHD and non-CHD groups was 69% and 81% at 1 year (p = 0.22) and 61% and 44% (p = 0.17) at 5 years, respectively. Octreotide-free survival after hepatectomy 69% and 84% (p = 0.15) at 1 year and 62% and 52% (p = 0.29) 5 years, respectively. Overall survival CHD and non-CHD groups 100% at 1 year and 100% and 70% (p = 0.002) 5 years.
Valve replacement for severe CHD is safe and hepatic resection is associated with similar outcomes as patients without CHD undergoing hepatic resection for carcinoid syndrome. Identifying resectable hepatic metastases from carcinoids in patients with severe CHD should prompt valve replacement and interval hepatic resection.
肝切除术治疗转移性类癌癌可以延长生存时间并控制症状性内分泌病。一些患有转移性类癌癌的患者可能会出现代偿性类癌性心脏病(CHD),这可能会排除可切除肝转移灶的手术。我们假设,对于因 CHD 而接受瓣膜置换术的类癌综合征患者,进行肝切除术的结果与无 CHD 的类癌患者相似。
我们比较了因 CHD 而接受瓣膜置换术的患者与无 CHD 的类癌患者的生存和症状控制情况,这些患者是根据年龄、性别和肝切除术范围相匹配的。
将 14 例因 CHD 而较早接受瓣膜置换术的患者与 28 例无 CHD 的类癌患者进行了比较。所有患者均因转移性类癌疾病和类癌综合征而行肝切除术。两组患者的平均年龄、性别分布和肝切除术范围(主要肝切除术,78%)相似。从瓣膜置换术到肝切除术的平均间隔时间为 101 天。无手术死亡。主要手术发病率,包括手术失血量和心肺事件,在 CHD 组和非 CHD 组分别为 28.5%和 14.2%(p=0.16)。CHD 组和非 CHD 组的无疾病生存情况分别为 1 年时的 69%和 81%(p=0.22)和 5 年时的 61%和 44%(p=0.17)。肝切除术后奥曲肽无生存情况分别为 1 年时的 69%和 84%(p=0.15)和 5 年时的 62%和 52%(p=0.29)。CHD 组和非 CHD 组的总生存情况分别为 1 年时的 100%和 100%以及 5 年时的 70%(p=0.002)。
严重 CHD 的瓣膜置换术是安全的,肝切除术与无 CHD 的患者因类癌综合征而行肝切除术的结果相似。在严重 CHD 患者中发现可切除的肝转移灶应促使进行瓣膜置换术和间隔肝切除术。